BioLineRx Past Earnings Performance
Past criteria checks 0/6
BioLineRx's earnings have been declining at an average annual rate of -14%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been growing at an average rate of 109.2% per year.
Key information
-14.0%
Earnings growth rate
37.3%
EPS growth rate
Biotechs Industry Growth | -24.5% |
Revenue growth rate | 109.2% |
Return on equity | -458.4% |
Net Margin | -1,262.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Does BioLineRx (TLV:BLRX) Have A Healthy Balance Sheet?
Apr 02BioLineRx (TLV:BLRX) Has Debt But No Earnings; Should You Worry?
Aug 25Health Check: How Prudently Does BioLineRx (TLV:BLRX) Use Debt?
Apr 05Is BioLineRx (TLV:BLRX) A Risky Investment?
Jun 17Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?
Feb 26Is BioLineRx (TLV:BLRX) Using Debt In A Risky Way?
Oct 17Revenue & Expenses BreakdownBeta
How BioLineRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 5 | -61 | 32 | 13 |
30 Sep 23 | 0 | -52 | 27 | 13 |
30 Jun 23 | 0 | -43 | 20 | 14 |
31 Mar 23 | 0 | -32 | 15 | 17 |
31 Dec 22 | 0 | -25 | 12 | 18 |
30 Sep 22 | 0 | -24 | 8 | 19 |
30 Jun 22 | 0 | -22 | 7 | 20 |
31 Mar 22 | 0 | -22 | 6 | 20 |
31 Dec 21 | 0 | -27 | 5 | 19 |
30 Sep 21 | 0 | -35 | 5 | 19 |
30 Jun 21 | 0 | -34 | 5 | 18 |
31 Mar 21 | 0 | -34 | 5 | 17 |
31 Dec 20 | 0 | -30 | 5 | 18 |
30 Sep 20 | 0 | -28 | 5 | 22 |
30 Jun 20 | 0 | -27 | 5 | 24 |
31 Mar 20 | 0 | -26 | 5 | 24 |
31 Dec 19 | 0 | -25 | 5 | 23 |
30 Sep 19 | 0 | -21 | 5 | 20 |
30 Jun 19 | 0 | -24 | 5 | 20 |
31 Mar 19 | 0 | -23 | 5 | 19 |
31 Dec 18 | 0 | -23 | 6 | 20 |
30 Sep 18 | 0 | -25 | 5 | 21 |
30 Jun 18 | 0 | -26 | 6 | 21 |
31 Mar 18 | 0 | -26 | 6 | 21 |
31 Dec 17 | 0 | -24 | 6 | 20 |
30 Sep 17 | 0 | -21 | 6 | 16 |
30 Jun 17 | 0 | -18 | 6 | 14 |
31 Mar 17 | 0 | -17 | 6 | 12 |
31 Dec 16 | 0 | -16 | 5 | 11 |
30 Sep 16 | 0 | -15 | 5 | 11 |
30 Jun 16 | 0 | -13 | 5 | 11 |
31 Mar 16 | 0 | -14 | 5 | 11 |
31 Dec 15 | 0 | -14 | 5 | 11 |
30 Sep 15 | 0 | -15 | 5 | 12 |
30 Jun 15 | 0 | -14 | 5 | 12 |
31 Mar 15 | 0 | -13 | 5 | 12 |
31 Dec 14 | 0 | -11 | 5 | 12 |
30 Sep 14 | 0 | -11 | 5 | 10 |
30 Jun 14 | 0 | -16 | 5 | 9 |
31 Mar 14 | 0 | -16 | 5 | 11 |
31 Dec 13 | 0 | -17 | 5 | 12 |
30 Sep 13 | 0 | -20 | 5 | 18 |
Quality Earnings: BLRX is currently unprofitable.
Growing Profit Margin: BLRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BLRX is unprofitable, and losses have increased over the past 5 years at a rate of 14% per year.
Accelerating Growth: Unable to compare BLRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: BLRX has a negative Return on Equity (-458.4%), as it is currently unprofitable.